Tech Company Financing Transactions
Apexigen Funding Round
Apexigen closed a $58 million Series C investment round on 8/10/2018. Investors included 3E Bioventures, SV Tech Ventures and Virtus Inspire Ventures.
Transaction Overview
Company Name
Announced On
8/10/2018
Transaction Type
Venture Equity
Amount
$58,000,000
Round
Series C
Investors
Proceeds Purpose
Apexigen intends to use these proceeds to advance the clinical development of its lead immuno-oncology (I-O) therapeutic APX005M, a monoclonal antibody targeting CD40.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
75 Shoreway Rd. C
Burlingame, CA 94070
USA
Burlingame, CA 94070
USA
Phone
Website
Email Address
Overview
Apexigen is a biopharmaceutical product development company developing products to address life-threatening and difficult to treat diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Xiaodong Yang
Chief Financial Officer
Linda Rubinstein
Chief Medical Officer
Ovid Trifan
Vice President
Rena Bahjat
Vice President
Thomas Jahn
Vice President
Jason Wright
VP - Bus. Development
Mark Nevins
VP - Finance
Amy Wong
Browse more venture capital transactions:
Prev: 8/10/2018: Relogix venture capital transaction
Next: 8/10/2018: Appetize venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to report on tech company VC transactions. VC transactions reported here are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs